Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 174

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Intravesical Gemcitabine and Docetaxel for the Treatment of Non-muscle Invasive Bladder Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Intravesical Gemcitabine and Docetaxel for the Treatment of Low Grade Intermediate Risk Bladder Cancer
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Enfortumab Vedotin and Pembrolizumab Plus Radiation Therapy for the Treatment of Muscle Invasive Bladder Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Stereotactic Radiotherapy and Enfortumab Vedotin for the Treatment of Patients with Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Enfortumab Vedotin with Concurrent Radiation Therapy for the Treatment of Locally Advanced Bladder Cancer, CONSOLIDATE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Sacituzumab Govitecan in Combination with Adaptive Radiation Therapy for Treatment of Patients with Muscle Invasive Bladder Cancer, RAD-SG Study
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination with Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer and Gastroesophageal Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients with Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Immunotherapy and Radiation Therapy after Surgery for the Treatment of Patients with Urothelial Bladder Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: Northwestern University, Chicago, Illinois
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Robotic Vascularized Composite Bladder Allograft Transplantation Surgery for the Treatment of Patients with Bladder Cancer
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
At-Home Delivery of Intravesical Bacille Calmette Guerin Solution with Chatbot Support for Treatment of Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy and/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts